Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.

Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.